{"id":72146,"date":"2026-08-10T12:37:32","date_gmt":"2026-08-10T04:37:32","guid":{"rendered":"https:\/\/flcube.com\/?p=72146"},"modified":"2026-08-10T12:37:33","modified_gmt":"2026-08-10T04:37:33","slug":"alebunds-ap301-nda-accepted-by-nmpa-for-hyperphosphatemia-in-ckd-dialysis-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72146","title":{"rendered":"Alebund&#8217;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Alebund Pharmaceuticals (Jiangsu) Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9637:HKG\">HKG:\u202f9637<\/a>) announced that the <strong>New Drug Application (NDA)<\/strong> for its core pipeline product <strong>AP301<\/strong>, indicated for the treatment of <strong>hyperphosphatemia<\/strong> in patients with <strong>chronic kidney disease (CKD)<\/strong> on maintenance dialysis, has been <strong>formally accepted<\/strong> by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The submission is anchored by positive data from the pivotal <strong>Phase\u202f3 RESPOND\u20111<\/strong> study conducted across 50 centers in China.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>AP301 (novel oral iron\u2011based phosphate binder)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hyperphosphatemia in CKD patients on maintenance dialysis<\/td><\/tr><tr><td><strong>NDA Acceptance Date<\/strong><\/td><td>07\u202fAug\u202f2026<\/td><\/tr><tr><td><strong>Key Study<\/strong><\/td><td>RESPOND\u20111 (Phase\u202f3, n\u202f=\u202f474, 50 centers in China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel oral <strong>iron\u2011based phosphate binder<\/strong><\/li>\n\n\n\n<li><strong>Class:<\/strong> Phosphate\u2011binding agent<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Binds dietary phosphate in the gastrointestinal tract via an iron\u2011based chelation platform, forming insoluble complexes that are excreted in feces, thereby lowering serum phosphorus levels<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Oral tablet<\/li>\n\n\n\n<li><strong>Differentiator:<\/strong> Iron\u2011based chemistry may offer a lower daily tablet burden compared with resin\u2011based binders such as sevelamer<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-respond-1-phase-3-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 RESPOND\u20111 Phase\u202f3 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>AP301<\/th><th>Sevelamer (Control)<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Serum Phosphorus Reduction (Week\u202f12)<\/strong><\/td><td><strong>0.72\u202fmmol\/L<\/strong><\/td><td>0.70\u202fmmol\/L<\/td><td><strong>Non\u2011inferiority met<\/strong><\/td><\/tr><tr><td><strong>Superiority (Low\u2011Dose Control Period)<\/strong><\/td><td>Maintenance dose<\/td><td>Suboptimal low dose<\/td><td><strong>P\u202f&lt;\u202f0.001<\/strong><\/td><\/tr><tr><td><strong>Serum Phosphorus Reduction (Week\u202f52)<\/strong><\/td><td><strong>0.76\u202fmmol\/L<\/strong><\/td><td>0.72\u202fmmol\/L<\/td><td>Numerically greater<\/td><\/tr><tr><td><strong>Serum Phosphorus Response Rate (Week\u202f52)<\/strong><\/td><td><strong>66.7\u202f%<\/strong><\/td><td>58.6\u202f%<\/td><td><strong>+8.1\u202fppt<\/strong><\/td><\/tr><tr><td><strong>Average Daily Tablet Burden<\/strong><\/td><td><strong>6.52\u202fg\/day<\/strong><\/td><td>7.56\u202fg\/day<\/td><td><strong>\u201313.8\u202f% lower<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Generally safe and well tolerated<\/td><td>\u2013<\/td><td>Comparable tolerability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The RESPOND\u20111 study enrolled <strong>474 hyperphosphatemia patients on maintenance dialysis<\/strong> across 50 Chinese centers. At Week\u202f12, AP301 demonstrated non\u2011inferior phosphorus lowering versus sevelamer. During the low\u2011dose control period, the AP301 maintenance dose showed <strong>statistically superior<\/strong> serum phosphorus control compared with the suboptimal low\u2011dose arm. By Week\u202f52, AP301 delivered a numerically deeper reduction in serum phosphorus alongside a higher response rate and a materially lower pill burden.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Dialysis Landscape:<\/strong> China has one of the world\u2019s largest dialysis populations, with hyperphosphatemia affecting the vast majority of maintenance dialysis patients. Current standard\u2011of\u2011care binders include sevelamer and lanthanum carbonate; an iron\u2011based alternative with comparable efficacy and lower pill burden could capture meaningful share.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> The <strong>13.8\u202f% reduction in daily tablet burden<\/strong> versus sevelamer is a clinically meaningful advantage in a patient population already burdened by polypharmacy, potentially improving adherence and outcomes.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts estimate the China phosphate\u2011binder market for dialysis patients at roughly <strong>\u00a54\u20135\u202fbillion<\/strong> (\u2248\u202fUS$560\u2013700\u202fmillion) annually. A competitively priced, domestically developed iron\u2011based binder could secure mid\u2011single\u2011digit market share within two years of launch.<\/li>\n\n\n\n<li><strong>Pipeline Positioning:<\/strong> AP301 is Alebund\u2019s <strong>core pipeline asset<\/strong>; NDA acceptance triggers a 12\u201318\u2011month regulatory review window and represents a critical inflection point toward the company\u2019s first major commercial product.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Unlike calcium\u2011based binders, AP301\u2019s iron\u2011based mechanism avoids calcium load, and unlike resin binders, it offers a lighter pill burden \u2014 a combination that may resonate with Chinese nephrologists seeking to optimize long\u2011term patient compliance.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the regulatory timeline, approval prospects, and commercial potential of AP301. Actual results may differ materially due to risks including NMPA review delays, bioequivalence or manufacturing inspection outcomes, competitive dynamics, pricing and reimbursement negotiations, and market adoption rates. Investors should consult official filings for updated risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700640.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080700640.\"><\/object><a id=\"wp-block-file--media-32fb811f-db8e-4f2a-9b62-9822eb580a2e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700640.pdf\">2026080700640<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700640.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-32fb811f-db8e-4f2a-9b62-9822eb580a2e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[627,4811,38],"class_list":["post-72146","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-alebund-pharmaceuticals","tag-hkg-9637","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alebund&#039;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core pipeline product AP301, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on maintenance dialysis, has been formally accepted by China\u2019s National Medical Products Administration (NMPA). The submission is anchored by positive data from the pivotal Phase\u202f3 RESPOND\u20111 study conducted across 50 centers in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72146\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alebund&#039;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients\" \/>\n<meta property=\"og:description\" content=\"Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core pipeline product AP301, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on maintenance dialysis, has been formally accepted by China\u2019s National Medical Products Administration (NMPA). The submission is anchored by positive data from the pivotal Phase\u202f3 RESPOND\u20111 study conducted across 50 centers in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72146\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T04:37:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T04:37:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72146#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72146\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alebund&#8217;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients\",\"datePublished\":\"2026-08-10T04:37:32+00:00\",\"dateModified\":\"2026-08-10T04:37:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72146\"},\"wordCount\":572,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alebund Pharmaceuticals\",\"HKG: 9637\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72146#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72146\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72146\",\"name\":\"Alebund's AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T04:37:32+00:00\",\"dateModified\":\"2026-08-10T04:37:33+00:00\",\"description\":\"Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core pipeline product AP301, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on maintenance dialysis, has been formally accepted by China\u2019s National Medical Products Administration (NMPA). The submission is anchored by positive data from the pivotal Phase\u202f3 RESPOND\u20111 study conducted across 50 centers in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72146#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72146\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72146#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alebund&#8217;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alebund's AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core pipeline product AP301, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on maintenance dialysis, has been formally accepted by China\u2019s National Medical Products Administration (NMPA). The submission is anchored by positive data from the pivotal Phase\u202f3 RESPOND\u20111 study conducted across 50 centers in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72146","og_locale":"en_US","og_type":"article","og_title":"Alebund's AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients","og_description":"Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core pipeline product AP301, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on maintenance dialysis, has been formally accepted by China\u2019s National Medical Products Administration (NMPA). The submission is anchored by positive data from the pivotal Phase\u202f3 RESPOND\u20111 study conducted across 50 centers in China.","og_url":"https:\/\/flcube.com\/?p=72146","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T04:37:32+00:00","article_modified_time":"2026-08-10T04:37:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72146#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72146"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alebund&#8217;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients","datePublished":"2026-08-10T04:37:32+00:00","dateModified":"2026-08-10T04:37:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72146"},"wordCount":572,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alebund Pharmaceuticals","HKG: 9637","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72146#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72146","url":"https:\/\/flcube.com\/?p=72146","name":"Alebund's AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T04:37:32+00:00","dateModified":"2026-08-10T04:37:33+00:00","description":"Alebund Pharmaceuticals (Jiangsu) Limited (HKG:\u202f9637) announced that the New Drug Application (NDA) for its core pipeline product AP301, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on maintenance dialysis, has been formally accepted by China\u2019s National Medical Products Administration (NMPA). The submission is anchored by positive data from the pivotal Phase\u202f3 RESPOND\u20111 study conducted across 50 centers in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72146#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72146"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72146#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alebund&#8217;s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72146"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72146\/revisions"}],"predecessor-version":[{"id":72148,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72146\/revisions\/72148"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}